Global Market for Anti-Obesity Drugs Report, Featuring Altimmune, Currax Pharmaceuticals, Eli Lilly, F. Hoffmann-La Roche, Glaxosmithkline, Novo Nordisk, Pfizer, Rhythm Pharmaceuticals and Vivus - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Market for Anti-obesity Drugs" report has been added to ResearchAndMarkets.com's offering.The report's scope includes an overview of the global market for anti-obe
Goldman Sachs Raises Obesity Drug Market Estimate to $130B
Buy Rating Affirmed for Altimmune on Promising Pemvidutide Data and Market Position
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be
Altimmune to Present Clinical Data From Pemvidutide at Upcoming EASL International Liver Congress 2024
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of
The era of scuffle is about to begin, who will become the next major product in the field of diet pills?
Currently, there are at least eight companies' weight loss candidates in the mid to late stages of development, including Pfizer, Amgen, Viking Therapeutics, Altimmune, Schudi Biotech, and Boehringer Ingelheim.
Institutional Owners May Ignore Altimmune, Inc.'s (NASDAQ:ALT) Recent US$69m Market Cap Decline as Longer-term Profits Stay in the Green
Key Insights Institutions' substantial holdings in Altimmune implies that they have significant influence over the company's share price 50% of the business is held by the top 24 shareholders Owne
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24
JMP Securities analyst Jonathan Wolleben maintains $Altimmune(ALT.US)$ with a buy rating, and maintains the target price at $24.According to TipRanks data, the analyst has a success rate of 42.9% and
Buy Rating Justified by Altimmune's Promising Pemvidutide Efficacy in NASH Treatment
Express News | Roundhill Investments Launches GLP-1 & Weight Loss ETF (Ozem)
Express News | HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target
Buy Rating Justified: Altimmune's Pemvidutide Shows Best-in-Class Potential for Obesity and MASH
Altimmune First Quarter 2024 Earnings: US$0.34 Loss per Share (Vs US$0.40 Loss in 1Q 2023)
Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Call Transcript
Altimmune Inc (ALT) Reports Q1 2024 Financials: A Detailed Review
Buy Rating Affirmed for Altimmune on Pemvidutide's Potential and Strategic Advancements
Altimmune Is Maintained at Market Outperform by JMP Securities
Altimmune Is Maintained at Market Outperform by JMP Securities
Express News | JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $24
Altimmune Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 213.32% JMP Securities $25 → $24 Maintains Market Outperform 04/29/2024 — Guggenheim Downgrade
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Evolent Health (EVH) and Cormedix (CRMD)
No Data